Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia

P. Vodárek, D. Écsiová, V. Řezáčová, O. Souček, M. Šimkovič, D. Vokurková, D. Belada, P. Žák, L. Smolej

. 2023 ; 12 (6) : 6956-6970. [pub] 20221128

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010679

BACKGROUND: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studied METHODS: We used multi-color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T-cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first-line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CIT RESULTS: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T-cells. After treatment, the percentage of naïve T-cells further decreased at the expense of effector memory T-cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T-cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T-cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T-cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041). CONCLUSION: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010679
003      
CZ-PrNML
005      
20230801132600.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.5492 $2 doi
035    __
$a (PubMed)36440594
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vodárek, Pavel $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000280507594 $7 xx0262638
245    12
$a A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia / $c P. Vodárek, D. Écsiová, V. Řezáčová, O. Souček, M. Šimkovič, D. Vokurková, D. Belada, P. Žák, L. Smolej
520    9_
$a BACKGROUND: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studied METHODS: We used multi-color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T-cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first-line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CIT RESULTS: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T-cells. After treatment, the percentage of naïve T-cells further decreased at the expense of effector memory T-cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T-cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T-cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T-cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041). CONCLUSION: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $7 D015451
650    _2
$a prognóza $7 D011379
650    _2
$a CD8-pozitivní T-lymfocyty $7 D018414
650    _2
$a podskupiny lymfocytů $7 D016131
650    _2
$a regulační T-lymfocyty $7 D050378
650    _2
$a T-lymfocyty - podskupiny $7 D016176
650    _2
$a CD4-pozitivní T-lymfocyty $7 D015496
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Écsiová, Dominika $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000268978756
700    1_
$a Řezáčová, Vladimíra $u Institute of Clinical Immunology and Allergology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000158021371
700    1_
$a Souček, Ondřej $u Institute of Clinical Immunology and Allergology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000331374200
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000303315334 $7 xx0117538
700    1_
$a Vokurková, Doris $u Institute of Clinical Immunology and Allergology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000169792825
700    1_
$a Belada, David $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000249816188 $7 mzk2006322730
700    1_
$a Žák, Pavel $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000344655343
700    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000241878595 $7 xx0101489
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 12, č. 6 (2023), s. 6956-6970
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36440594 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132557 $b ABA008
999    __
$a ok $b bmc $g 1963248 $s 1196944
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 12 $c 6 $d 6956-6970 $e 20221128 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...